Quantcast

Latest Omalizumab Stories

2014-10-01 23:02:26

The Firm is evaluating legal claims on behalf of individuals who allegedly suffered serious Xolair side effects, including heart attacks, mini-strokes, pulmonary hypertension, and blood clots in the lungs and veins. New York, New York (PRWEB) October 01, 2014 The nationwide law firm of Bernstein Liebhard LLP is now evaluating Xolair side effect claims (http://www.consumerinjurylawyers.com/xolair-lawsuit) on behalf of individuals who allegedly suffered serious health issues that may be...

2014-10-01 08:31:01

-- Today is the first ever International Urticaria Day, an international event to increase urticaria awareness and improve care around the globe and let people living with urticaria know they are not alone -- Skin Impressions campaign aims to break down barriers preventing people suffering from severe skin diseases like chronic idiopathic urticaria (CIU) from living lives to the fullest -- CIU is an unpredictable skin disease characterized by...

2014-09-30 23:24:57

On September 26, the FDA issued a safety communication on potential risks of cardiovascular and cerebrovascular serious adverse events to Xolair's (omalizumab) drug label. In light of this news, AttorneyOne, a recognized authority on law, updated the website providing detailed information to consumers. San Diego, CA (PRWEB) September 30, 2014 AttorneyOne.com, a recognized authority on law, update the website daily regarding all the latest information from the FDA on Xolair...

2014-08-21 12:25:49

Efficacy on Reducing Exacerbations and Hospitalizations is One of the Key Drug Attributes for Formulary Inclusion, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 21, 2014 /PRNewswire/ -- Decision Resources Group finds that the asthma market in Brazil and Mexico currently faces severe coverage restrictions. The uptake of several newly approved agents, the anticipated label extension of Boehringer Ingelheim/Pfizer's Spiriva for this indication and the launch of...

2014-07-31 16:28:27

Conference call today at 4:30 p.m. EDT MONROVIA, Calif., July 31, 2014 /PRNewswire/ -- Xencor Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today reported financial results for the second quarter ended June 30, 2014 and provided a review of recent business highlights. "In the second quarter, we presented preclinical data at the American Thoracic...

2014-07-24 12:27:40

While Expressing Concerns about Reimbursement, EU5 Payers Look Favorably on Identifying Anti-IL5 Therapy-Responsive Patients, According to Findings from Decision Resources Group BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid...

2014-05-28 08:31:16

MONROVIA, Calif., May 28, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the first subject has been dosed in a Phase 1a clinical trial of XmAb®7195. XmAb7195 is a monoclonal antibody engineered to suppress IgE via three distinct mechanisms of action as a potential treatment for asthma and...

2014-05-15 08:32:10

Rapid IgE clearance by XmAb7195 shows potential as a disease modifying treatment for allergy and asthma MONROVIA, Calif., May 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced it will present preclinical data comparing activity of XmAb®7195 to omalizumab in reducing IgE, a protein responsible...

2014-05-01 12:28:46

Reduction in Exacerbations Remains the Top Driver of Physician Prescribing Choice in Moderate to Severe Asthma, According to Findings from Decision Resources Group BURLINGTON, Mass., May 1, 2014 /PRNewswire/ -- Decision Resources Group finds that 90 percent of surveyed U.S. payers indicated a willingness to pay a premium-price for a novel therapy with substantially greater improvements in reducing exacerbations than Genentech/Novartis's Xolair in the treatment of severe asthma. Surveyed U.S....

2014-03-21 16:23:03

- First-in-class medicine approved for CIU, a burdensome skin condition that can cause hives, severe itch, and swelling that can last many months and years EAST HANOVER, N.J., March 21, 2014 /PRNewswire/ -- Novartis today announced that the US Food and Drug Administration (FDA) approved Xolair(®) (omalizumab) for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives. The new use is for patients 12 years of age and older who remain symptomatic despite treatment with...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related